BackPhathom Pharmaceuticals Overview
Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals Target Price

Where could PHAT trade next? Consensus target price: $17.

Get informed when a big investor buys or sells

+ Follow

Share Price

$5.68

Average Target Price

$17.00199.3% upside

7 analysts in the last 4 months

High: $22 | Low: $10

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-10-21Craig-HallumChase Knickerbocker$15164.1% upsideOpen
2026-10-14JefferiesGlen Santangelo$16181.7% upsideOpen
2026-09-09Leerink Partners$1076.1% upsideOpen
2026-08-14Barclays$14146.5% upsideOpen
2026-07-31Craig-HallumChase Knickerbocker$20252.1% upsideOpen
2026-07-31Guggenheim$22287.3% upsideOpen
2026-07-30Needham$22287.3% upsideOpen
2026-03-27BarclaysJenna Davidner$18216.9% upsideOpen
2026-02-26Stifel NicolausAnnabel Samimy$28393% upsideOpen
2025-12-11Raymond JamesMartin Auster$28393% upsideOpen
2025-12-08BarclaysJenna Davidner$16181.7% upsideOpen
2025-10-31Craig-HallumChase Knickerbocker$22287.3% upsideOpen
2025-10-31H.C. Wainwright$26357.7% upsideOpen
2025-10-30GuggenheimYatin Suneja$20252.1% upsideOpen
2025-03-07Guggenheim$18216.9% upsideOpen
2024-08-08Goldman SachsPaul Choi$12111.3% upsideOpen
2024-07-19H.C. WainwrightMatthew Caufield$28393% upsideOpen
2024-05-02Stifel NicolausAnnabel Samimy$24322.5% upsideOpen
2024-01-05NeedhamJoseph Stringer$26357.7% upsideOpen
2023-01-04BMO Capital$35516.2% upsideOpen
2023-01-04Needham$25340.1% upsideOpen
2022-11-14BMO Capital$38569% upsideOpen
2022-11-11Guggenheim$30428.2% upsideOpen

Phathom Pharmaceuticals (PHAT) FAQ

The latest target price for PHAT is $17. Investors often review this figure alongside Phathom Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Phathom Pharmaceuticals trades near $5.68 while the consensus target sits at $17 (199.3% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting PHAT's target price ($17), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Phathom Pharmaceuticals's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.